NCT06563271

Brief Summary

The aim of this study is to evaluate the short-term effects of routinely applied agents on pain and joint range of motion (ROM) in ankle sprains presenting to the emergency department (ED).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Dec 2023

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 8, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 20, 2024

Completed
Last Updated

August 20, 2024

Status Verified

August 1, 2024

Enrollment Period

5 months

First QC Date

July 8, 2024

Last Update Submit

August 19, 2024

Conditions

Keywords

Range of motionNumerical Rating Scale

Outcome Measures

Primary Outcomes (3)

  • To evaluate the effectiveness of multimodal treatment methods on pain in ankle sprains.

    Numeric Rang Scale (NRS) will be used to assess effects on pain. NRS: This scale uses 11 numbers from 0 to 10 to measure pain intensity, where 0 represents "No pain" and 10 represents "Worst (unbearable) pain."

    *Patient's pain level, NRS Scale: - 0 minute before treatment -15 minute after treatment -60 minute after treatment

  • To evaluate the effectiveness of multimodal treatment methods on pain in ankle sprains.

    Wong-Baker FACES pain rating scale (WBS) will be used to assess effects on pain. WBS: This scale uses a series of faces ranging from a smiling face representing "No pain" to a crying face representing "Worst pain" to visually express the intensity of pain.

    *Wong-Baker Faces Pain Rating Scale: - 0 minute before treatment -15 minute after treatment -60 minute after treatment

  • To evaluate the effectiveness of multimodal treatment methods on Range of Motion in ankle sprains.

    A standard handheld goniometer will be used to calculate Range of Motion (ROM) measurements. The aim is to determine the effects of multimodal treatment methods routinely applied in emergency services on pain and range of motion and to reveal their superiority over each other, if any. (Normal ROM values: 20° for dorsiflexion, 45° for plantar flexion)

    - 0 minute ROM before treatment - 60 minute ROM after treatment

Study Arms (3)

Group Dexketoprofen

ACTIVE COMPARATOR

Dexketoprofen 50 mg will be administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Drug: Dexketoprofen Trometamol 50 Mg/mL Solution for InjectionDrug: isotonic saline

Group Ibuprofen

ACTIVE COMPARATOR

Ibuprofen 100 mg/ml will be administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Drug: Ibuprofen 100 MG/ML Solution for InjectionDrug: isotonic saline

Group Paracetamol

ACTIVE COMPARATOR

Paracetamol 10 mg/ml will be administered parenterally.

Drug: Paracetamol 10 Mg/mL Solution for Injection

Interventions

Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Group Dexketoprofen

Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion). Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Group Ibuprofen

Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Group Paracetamol

Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.

Group DexketoprofenGroup Ibuprofen

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18 years and older who present to the emergency department within the first 72 hours after ankle sprain.
  • Grade 1 (mild) and Grade 2 (moderate) ankle sprains.
  • Absence of muscle-tendon ruptures.
  • Absence of vascular and nerve injuries.
  • Absence of open wounds and burns.
  • Stable vital signs.
  • Patients who provide written and verbal consent.

You may not qualify if:

  • Patients who did not present to the emergency department within the first 72 hours after ankle sprain.
  • Grade 3 (severe) ankle sprains.
  • Multiple traumas.
  • Pregnancy or suspected pregnancy.
  • Ankle fractures and dislocations.
  • Forensic cases.
  • History of previous ankle surgery or fracture.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Etlik City Hospital

Ankara, Yenimahalle, 38000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Ankle Injuries

Interventions

dexketoprofen trometamolSolutionsInjectionsIbuprofenAcetaminophenSodium Chloride

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and Injuries

Intervention Hierarchy (Ancestors)

Pharmaceutical PreparationsDrug Administration RoutesDrug TherapyTherapeuticsPhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAcetanilidesAnilidesAmidesAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Ahmet B. Erdem

    Ankara Etlik City Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

July 8, 2024

First Posted

August 20, 2024

Study Start

December 1, 2023

Primary Completion

May 1, 2024

Study Completion

June 1, 2024

Last Updated

August 20, 2024

Record last verified: 2024-08

Locations